Literature DB >> 35686662

Potential therapeutic effects of Ivermectin in COVID-19.

Nastaran Barati1,2, Seyedmousa Motavallihaghi3, Banafsheh Nikfar4, Shahla Chaichian4, Amir Abbas Momtazi-Borojeni5.   

Abstract

COVID-19 is a critical pandemic that affected communities around the world, and there is currently no specific drug treatment for it. The virus enters the human cells via spikes and induces cytokine production and finally arrests the cell cycle. Ivermectin shows therapeutic potential for treating COVID-19 infection based on in vitro studies. Docking studies have shown a strong affinity between Ivermectin and some virulence factors of COVID-19. Notably, clinical evidence has demonstrated that Ivermectin with usual doses is effective by both the prophylactic and therapeutic approaches in all phases of the disease. Ivermectin inhibits both the adhesion and replication of the virus. Local therapy of the lung with Ivermectin or combination therapy may get better results and decrease the dose of the drug.

Entities:  

Keywords:  COVID-19; Ivermectin; SARS-CoV-2; hypoxia-inducible factor-alpha; importin; inflammation; lung; pandemics

Mesh:

Substances:

Year:  2022        PMID: 35686662      PMCID: PMC9442455          DOI: 10.1177/15353702221099579

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  99 in total

1.  The effect of protein binding on ivermectin uptake by bovine brain microvessel endothelial cells.

Authors:  K L Audus; S R Knaub; F L Guillot; J M Schaeffer
Journal:  Vet Res Commun       Date:  1992       Impact factor: 2.459

2.  A comparison of glycine- and ivermectin-mediated conformational changes in the glycine receptor ligand-binding domain.

Authors:  Qian Wang; Joseph W Lynch
Journal:  Int J Biochem Cell Biol       Date:  2011-11-11       Impact factor: 5.085

3.  Molecular determinants of ivermectin sensitivity at the glycine receptor chloride channel.

Authors:  Timothy Lynagh; Timothy I Webb; Christine L Dixon; Brett A Cromer; Joseph W Lynch
Journal:  J Biol Chem       Date:  2011-10-27       Impact factor: 5.157

4.  [Ivermectin inhibits activation of Kupffer cells induced by lipopolysaccharide toxin].

Authors:  A V Viktorov
Journal:  Antibiot Khimioter       Date:  2003

5.  The Battle against COVID 19 Pandemic: What we Need to Know Before we "Test Fire" Ivermectin.

Authors:  Kushal Banerjee; Manab Nandy; Chanchal Kumar Dalai; Shah Newaz Ahmed
Journal:  Drug Res (Stuttg)       Date:  2020-06-19

6.  White paper on Ivermectin as a potential therapy for COVID-19.

Authors:  Agam Vora; V K Arora; D Behera; Surya Kant Tripathy
Journal:  Indian J Tuberc       Date:  2020-07

Review 7.  Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication.

Authors:  Zheng Yao Low; Ashley Jia Wen Yip; Sunil K Lal
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-10-20       Impact factor: 5.187

Review 8.  Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach.

Authors:  Ahmad Abu Turab Naqvi; Kisa Fatima; Taj Mohammad; Urooj Fatima; Indrakant K Singh; Archana Singh; Shaikh Muhammad Atif; Gururao Hariprasad; Gulam Mustafa Hasan; Md Imtaiyaz Hassan
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-06-13       Impact factor: 5.187

9.  Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats.

Authors:  Carlos Chaccour; Gloria Abizanda; Ángel Irigoyen-Barrio; Aina Casellas; Azucena Aldaz; Fernando Martínez-Galán; Felix Hammann; Ana Gloria Gil
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

10.  The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19.

Authors:  Virginia D Schmith; Jie Jessie Zhou; Lauren R L Lohmer
Journal:  Clin Pharmacol Ther       Date:  2020-06-07       Impact factor: 6.903

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.